Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
CymaBay Therapeutics (NASDAQ:CBAY) Downgraded to Hold at Zacks Investment Research
10:18am, Sunday, 12'th Apr 2020
Zacks Investment Research cut shares of CymaBay Therapeutics (NASDAQ:CBAY) from a buy rating to a hold rating in a research note issued to investors on Thursday morning, Zacks.com reports. According t
Credit Suisse AG Lowers Holdings in CymaBay Therapeutics Inc (NASDAQ:CBAY)
08:20am, Sunday, 12'th Apr 2020
Credit Suisse AG trimmed its holdings in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 23.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.
Jane Street Group LLC Takes Position in CymaBay Therapeutics Inc (NASDAQ:CBAY)
11:07am, Saturday, 11'th Apr 2020
Jane Street Group LLC purchased a new stake in CymaBay Therapeutics Inc (NASDAQ:CBAY) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor pu
Edited Transcript of CBAY earnings conference call or presentation 12-Mar-20 8:30pm GMT
11:32am, Wednesday, 01'st Apr 2020
Q4 2019 Cymabay Therapeutics Inc Earnings Call
Edited Transcript of CBAY earnings conference call or presentation 12-Mar-20 8:30pm GMT
06:12am, Wednesday, 01'st Apr 2020
Q4 2019 Cymabay Therapeutics Inc Earnings Call
In Biotech ‘Cash Is King’ When Wall Street Searches for Value
06:04pm, Wednesday, 25'th Mar 2020
(Bloomberg) -- For investors looking for deals in biotech, Wall Street firms like Baird advise “cash is king.”Losses in the U.S. stock market have decimated many portfolios. And while biotechnolog
CymaBay Therapeutics Inc (NASDAQ:CBAY) Shares Bought by Jefferies Group LLC
11:30am, Monday, 23'rd Mar 2020
Jefferies Group LLC boosted its position in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) by 461.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The
Citigroup Cuts CymaBay Therapeutics (NASDAQ:CBAY) Price Target to $1.60
10:34am, Monday, 23'rd Mar 2020
CymaBay Therapeutics (NASDAQ:CBAY) had its target price cut by Citigroup from $2.00 to $1.60 in a report released on Friday, BenzingaRatingsTable reports. They currently have a buy rating on the bioph
Equities Analysts Issue Forecasts for CymaBay Therapeutics Inc's Q1 2020 Earnings (NASDAQ:CBAY)
05:37am, Monday, 23'rd Mar 2020
CymaBay Therapeutics Inc (NASDAQ:CBAY) – Oppenheimer raised their Q1 2020 earnings per share estimates for CymaBay Therapeutics in a note issued to investors on Wednesday, March 18th. Oppenheimer an
Barclays PLC Has $149,000 Stake in CymaBay Therapeutics Inc (NASDAQ:CBAY)
10:56am, Saturday, 21'st Mar 2020
Barclays PLC decreased its stake in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) by 90.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Comm
B. Riley Weighs in on CymaBay Therapeutics Inc's FY2020 Earnings (NASDAQ:CBAY)
08:34am, Saturday, 21'st Mar 2020
CymaBay Therapeutics Inc (NASDAQ:CBAY) – Stock analysts at B. Riley decreased their FY2020 earnings per share (EPS) estimates for shares of CymaBay Therapeutics in a research note issued on Tuesday,
CymaBay Therapeutics Inc (NASDAQ:CBAY) Given Consensus Rating of "Hold" by Brokerages
07:28am, Saturday, 21'st Mar 2020
CymaBay Therapeutics Inc (NASDAQ:CBAY) has been assigned a consensus rating of “Hold” from the fifteen ratings firms that are currently covering the stock, MarketBeat.com reports. One investment a
13D Filings
12:30am, Saturday, 21'st Mar 2020
Activist investor filings with the SEC on Lindblad Expeditions Holdings, Kala Pharmaceuticals, Avid Technology, Xoma, CymaBay, and National Fuel Gas
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
02:44pm, Friday, 20'th Mar 2020
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
02:44pm, Friday, 20'th Mar 2020
Stabilizing prices of generic drugs have led to recovery in the industry. New launches have also provided a boost. However, coronavirus crisis creates an uncertainty for the industry.
